StoneX Group Inc. Purchases Shares of 66,103 Genmab A/S (NASDAQ:GMAB)

StoneX Group Inc. bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 66,103 shares of the company's stock, valued at approximately $1,380,000.

A number of other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Cromwell Holdings LLC grew its holdings in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Genmab A/S during the fourth quarter worth $93,000. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GMAB has been the topic of a number of analyst reports. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Truist Financial cut their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and an average target price of $41.33.

Remove Ads

Genmab A/S Stock Up 2.2 %

GMAB traded up $0.42 on Thursday, hitting $19.24. The company's stock had a trading volume of 1,715,372 shares, compared to its average volume of 974,158. Genmab A/S has a 12 month low of $18.48 and a 12 month high of $30.50. The firm has a market cap of $12.73 billion, a P/E ratio of 11.06, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company's 50 day simple moving average is $20.72 and its 200-day simple moving average is $21.70.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.